Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 2 art units • 3 examiners • 0 of 4 (0%) have an AI response strategy ready
Locus Biosciences Inc. manages 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These cases are handled by 3 distinct examiners across 2 distinct art units. LIPPOLIS, ALEXANDRA ROSE is the busiest examiner, managing 2 pending office actions. This indicates that while the workload is distributed, a significant portion of the company's current patent prosecution is concentrated under a single examiner.
With 4 pending office actions, the portfolio shows a moderate level of activity. The involvement of 3 distinct examiners provides some variety in the examination process, but the concentration of 2 cases under LIPPOLIS, ALEXANDRA ROSE makes her the most influential figure in the current portfolio. The 2 distinct art units involved suggest that the company's technology is being evaluated under different sets of examination guidelines. Practitioners should tailor their arguments to the specific requirements of these 2 distinct art units while maintaining a consistent strategy across the 3 distinct examiners.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| §112 only | 3 (75%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LIPPOLIS, ALEXANDRA ROSE | 2 | 46.9% | +59.0% |
| VYAS, KEYUR ANILKUMAR | 1 | 49.4% | +60.8% |
| BATES, KEENAN ALEXANDER | 1 | 45.5% | +79.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17774393 | PHAGE COMPOSITIONS COMPRISING CRISPR-CAS SYSTEMS AND METHODS OF USE THEREOF | LIPPOLIS, ALEXANDRA ROSE | 15d |
| 18035227 | PHAGE COMPOSITIONS FOR PSEUDOMONAS COMPRISING CRISPR-CAS SYSTEMS AND METHODS OF USE THEREOF | VYAS, KEYUR ANILKUMAR | — |
| 18033988 | PHAGE COMPOSITIONS FOR ESCHERICHIA COMPRISING CRISPR-CAS SYSTEMS AND METHODS OF USE THEREOF | BATES, KEENAN ALEXANDER | — |
| 17774360 | PHAGE COMPOSITIONS COMPRISING CRISPR-CAS SYSTEMS AND METHODS OF USE THEREOF | LIPPOLIS, ALEXANDRA ROSE | — |
| Art Unit | Apps |
|---|---|
| 1637 | 3 |
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18035227 | PHAGE COMPOSITIONS FOR PSEUDOMONAS COMPRISING CRISPR-CAS SYSTEMS AND METHODS OF USE THEREOF | VYAS, KEYUR ANILKUMAR | 1637 | §112 | Non-Final OA | — | Pending | May 08, 2023 |
| 18033988 | PHAGE COMPOSITIONS FOR ESCHERICHIA COMPRISING CRISPR-CAS SYSTEMS AND METHODS OF USE THEREOF | BATES, KEENAN ALEXANDER | 1631 | §112 | Final Rejection | — | Pending | Apr 26, 2023 |
| 17774360 | PHAGE COMPOSITIONS COMPRISING CRISPR-CAS SYSTEMS AND METHODS OF USE THEREOF | LIPPOLIS, ALEXANDRA ROSE | 1637 | §112 | Final Rejection | — | Pending | May 04, 2022 |
| 17774393 | PHAGE COMPOSITIONS COMPRISING CRISPR-CAS SYSTEMS AND METHODS OF USE THEREOF | LIPPOLIS, ALEXANDRA ROSE | 1637 | §103 | Non-Final OA | 15d | Pending | May 04, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial